Navigation Links
New agent strikes at respiratory syncytial virus replication
Date:5/5/2008

GALVESTON, Texas University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

In an effort to find an effective antiviral therapy for RSV, the scientists tested two types of complex, custom-designed molecule to interfere with the genetic machinery that RSV uses to replicate, or copy itself, within cells. Both of the so-called morpholino oligomers, created by Oregon-based AVI BioPharma, penetrated cultured human airway cells easily and produced only minimal toxicity. One of the two, designated AUG-2, significantly reduced RSV replication in both cell culture and mouse experiments.

Viral replication is one of the major pathogenetic processes of RSV, and we badly need a specific antiviral therapy, said UTMB Dr. Roberto Garofalo, senior author of a paper on the study to be published in the June issue of Molecular Therapy and now available in the Advance Online Publication section of the journals website. That's what an agent like this morpholino could give us.

RSV infects almost all children by age two, but normally causes only a cold-like upper respiratory infection. In some babies, however, it spreads to the lungs, where the inflammation it generates causes coughing, wheezing and extreme difficulty in breathing, a life-threatening clinical syndrome known as bronchiolitis.

Recent research by Garofalo and other investigators suggests that two key factors drive RSV bronchiolitis: an inflammatory overreaction by the cells that line the airways of the lungs, and a failure to respond to RSV by T lymphocytes (also known as T cells), immune system cells that ordinarily act to control viral infections.

Because a dangerous inflammatory response occurs so soon after RSV begins replicating in the lungs, Garofalo said, antiviral therapy by itself is unlikely to be sufficient to treat severe RSV infection in infants. But it could be a critical part of a combination therapy that also included drugs to reduce RSV-induced lung inflammation and boost T-cell response.

The virus continues to replicate for days in the lungs of infected infants, and it induces inflammation as long as it replicates, Garofalo said. So stopping viral replication would be a very important part of any therapeutic strategy for RSV.


'/>"/>
Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
2. China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent
3. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
4. Peter Burg Appointed as Co-Chair of the Plaintiffs Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation
5. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
6. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
9. IUPUI scientists report first 3-D view of anti-cancer agent
10. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
11. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 19, 2017 , ... DMG Productions, producers of the ... in an upcoming episode, slated to air fourth quarter 2017. Check your local ... Group; a company committed to supporting dentistry using the most technologically advanced restorative ...
(Date:8/19/2017)... , ... August 18, 2017 , ... ... Administration Reauthorization Act of 2017, legislation that provides for greater public access to ... moderate hearing loss to access OTC hearing aids without being seen by a ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity of ... in prints in a wide range of sizes. These illustrations are also available ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of ... location as an interventional pain management physician. He brings a wealth of pain ... migraine headaches, and significant experience in spinal cord stimulation for chronic pain. , ...
(Date:8/18/2017)... , ... August 18, 2017 , ... More than 20,000 ... Republic of Congo (DRC) thanks to an ambitious venture that conjoined the passions of ... the generous support of the Liberty community. These shoes will save lives from the ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
Breaking Medicine Technology: